The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients

Biomedicine and Pharmacotherapy

Volumn 58, Issue 4, 2004, Pages 255-259

  Zilembo, Nicoletta ^a   Bajetta, Emilio ^a   Bichisao, Ettore ^b   Martinetti, Antonia ^a   La Torre, Ignazia ^a   Bidoli, Paolo ^a   Longarini, Raffaella ^a   Portale, Tindara ^a   Seregni, Ettore ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ITMO   (Italy)

Author keywords

Advanced breast cancer; Aromatase inhibitors; Estrogen suppression; Formestane

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; FORMESTANE; LETROZOLE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ESTROGEN BLOOD LEVEL; FEMALE; FLUSHING; FOLLOW UP; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTRADIOL;

EID: 19244365879     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.12.009     Document Type: Article

References (18)

1. Bajetta E., Zilembo N., Barni S., Noberasco C., Martinetti A., Ferrari L., et al. On behalf of the Italian Trials in Medical Oncology (I.T.M.O.) Group: a multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. Ann Oncol. 8:1997;649-654
2. Bajetta E., Zilembo N., Bichisao E., Martinetti A., Buzzoni R., Pozzi P., et al. Tumor response and oestrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann Oncol. 11:2000;1017-1022
3. Bajetta E., Zilembo N., Buzzoni R., Noberasco C., Di Leo A., Bartoli C., et al. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. Br J Cancer. 70:1994;145-150
4. Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thurlimann B., von Euler M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92:2001;2247-2258
5. Brodie A.M.H., Njar V.C.O. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol. 66:1998;1-10
6. Buzdar A.U., Jonat W., Howell A., Jones S.E., Blomqvist C.P., Vogel C.L., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 83:1998;1142-1152. Arimidex Study Group
7. Carlini P., Frassoldati A., De Marco S., Casali A., Ruggeri E.M., Nardi M., et al. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Ann Oncol. 12:2001;1539-1543
8. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 16:1998;453-461
9. Hayward J.L., Rubens R.D., Carbone P.P., Hensom J.C., Kumooka S., Segaloff A. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 35:1977;292-298
10. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomised double-blind trial. J Clin Oncol. 18:2000;1399-1411
11. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 21:2003;1383-1389
12. Lonning P.E., Bajetta E., Murray R., Tubiana_Hulin M., Eisenberg P.D., Mickiewicz E., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J Clin Oncol. 18:2000;2234-2244
13. Martinetti A., Seregni E., Bajetta E., Bolelli G.F., Ferrari L., Massaron S., et al. Development of a rapid ultrasensitive RIA method for estrogen (E1, E2, E1-S) determination with selective solid phase extraction. Int J Biol Markers. 12:1997;102-105
14. Mouridsen H., Gersanovich M., Sun Y., Perez_Carrion R., Boni C., Monnier A., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the international Letrozole Breast Cancer Group. J Clin Oncol. 19:2001;2596-2606
15. Murray R., Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat. 35:1995;249-253
16. Thurlimann B., Paridaens R., Serin D., Bonneterre J., Roche H., Murray R., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a Phase II, multicenter multinational study. Eur J Cancer. 33:1997;1767-1773. Exemestane Study Group
17. Wiseman L.R., McTavish D. Formestane: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs. 45:(1):1993;66-84
18. Zilembo N., Buzzoni R., Celio L., Noberasco C., Ferrari L., Laffranchi A., et al. Formestane as treatment of advanced breast cancer in elderly women. Tumori. 80:1994;433-437